ArticleFrontiers in oncology2026
Vulnerability index impacts distribution of prostate cancer clinical trials in the United States.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Availability of clinical trials for prostate cancer in the US varies greatly by region. County-level analyses are vital to characterize healthcare access, disease burden, and population-level disparities. Methods: Utilizing the ClinicalTrials.gov trial database, we collated all interventional prostate cancer trials between June 1, 2019, and June 1, 2025. We compiled data on county characteristics along with Social Vulnerability Index (SVI) designations derived from the CDC, NCI, and the Agency for Toxic Substances and Disease Registry data. A zero-inflated negative binomial regression model was used to evaluate trial availability. Trial characteristics were summarized using descriptive analysis. Results: We found 884 eligible trials. Among 3,145 counties, only 631 had at least one clinical trial over the study period. Most trials (51%) included patients with metastatic disease. Sixteen percent of trials investigated curative treatments, while 65% examined palliative interventions. The majority of studies (52.5%) had funding from pharmaceutical companies. There was no significant relationship between trial availability and incidence or mortality rates. Among counties with at least one trial, those with a low SVI had twice as many trials per household when compared to those with high SVI (IRR 2.05, 95% CI 1.54 - 2.74, p<0.001). Counties with no trials were more rural (72.3% vs 22.0%) and had fewer specialist physicians (17.1% vs 69.1%). Conclusion: Prostate cancer trials are disproportionately concentrated in the US, with lower representation in vulnerable areas. Expanding trial access to underserved areas is a crucial step in promoting equitable access to care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.